SecBot SecBot
Insider Cluster (2 insiders) ·Filed Nov 3, 2026

ARTV

Artiva Biotherapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed13d 9h ago
Insider cluster: 2 insiders, $265K total
Actionable Insight ▼ Bearish

The CEO's unplanned open-market sale immediately after a clinical failure and restructuring signals insider belief that the strategic alternatives process may not yield a favorable outcome for equity holders. Monitor for any definitive agreement or dissolution filing; the $319M cash cushion may attract acquirers but the clinical setback severely limits valuation.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

ARTV drug pipeline →

AB-101

● Neutral Named in this insider cluster
Impact
Phase
Phase 1a/1b
Time to market
AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
Next catalyst
None dated

What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$4.22
T+0 close · Nov 3, 2026 · via day close
Latest settled
−3.55%
T+5 · $4.07 · next T+20 in 16d
Vs SPY
−2.64%
α at T+5
Latest observation
−3.99%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $4.22entry
  2. T+1 · 12d ago −2.13%α +2.28% · $4.13
  3. T+5 · 6d ago −3.55%α −2.64% · $4.07
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO and CMO sold shares days after the company discontinued its sole pipeline candidate, announced a 94% workforce reduction, and began evaluating strategic alternatives including a possible sale or dissolution. The CEO's $260K open-market sale is material relative to the $207M market cap (0.13%), signaling insider pessimism following the clinical failure.

Key Financial Metrics

Direction
selling
Total Value
$265.0K
Insiders
2

Key Facts

  • CEO Fred Aslan sold 62,178 shares at $4.18 for $260K on 2026-11-02, no 10b5-1 plan
  • CMO Subhashis Banerjee sold 1,110 shares at $4.18 for $5K on 2026-11-02, no 10b5-1 plan
  • On 2026-10-27, Artiva discontinued AlloNK (AB-101) after insufficient durability and two Grade 5 safety events
  • Company reducing workforce by ~94% and exploring strategic alternatives including merger, sale, or dissolution
  • Preliminary cash and investments were ~$319.1M as of Sep 30, 2026
  • Total insider sales in the cluster: $265K, representing 0.13% of market cap
  • Market cap: $207M; normal daily move: 3.8%

Financial Impact

CEO open-market sale of $260K (0.13% of market cap) days after clinical failure and restructuring announcement

market capinsider ownership

Risk Factors

  • Potential dissolution or fire-sale merger with limited equity value recovery
  • Further insider selling as remaining executives exit
  • No pipeline assets remaining after AlloNK discontinuation

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
58% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ARTV-1793739928357

Track record

33 reports on ARTV

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Viewing Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 7h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026